

JC17 Rec'd PCT/PTO 24 MAR 2005

EXPRESS MAIL LABEL NO. EV514605796US

Date of Deposit: March 24, 2005

10/529118

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66904-02
Application Number	10/529,118
Filing Date	Herewith 3/24/05
First Named Inventor	Cuttitta
Art Unit	1618
Examiner Name	De Jones

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
DF		2002/0055615	May 9, 2002	Cuttitta <i>et al.</i>
		5,639,855	June 17, 1997	Kitamura <i>et al.</i>
		5,910,416	June 8, 1999	Kitamura <i>et al.</i>
		6,320,022	November 20, 2001	Cuttitta <i>et al.</i>
DF		6,440,421	August 27, 2002	Cornish <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
DF		Europe	0 845 036	June 2, 1999	Cuttitta <i>et al.</i>
		Europe	0 926 238 A2 & A3	November 22, 2000	Poste
		PCT	WO 97/07214	February 27, 1997	Cuttitta <i>et al.</i>
		PCT	WO 01/18550	March 15, 2001	Cuttitta <i>et al.</i>
DF		PCT	WO 2004/043383	May 27, 2004	Cuttitta <i>et al.</i>

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
DF		Corti <i>et al.</i> , "Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease," <i>Cardiovascular Drugs</i> 104:1856-1862 (October 9, 2001)
DF		Fernandez-Patron, "Vascular Matrix Metalloproteinase-2-Dependent Cleavage of Calcitonin Gene-Related Peptide Promotes Vasoconstriction," <i>Circ Res.</i> 87:670-676 (2000)

EXAMINER
SIGNATURE:

De Jones


DATE


CONSIDERED:


2/12/07

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/529118

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66904-02
		Application Number	617 Rec'd PGI/PTO 24 MAR 2005
		Filing Date	Herewith 3/24/05
		First Named Inventor	Cuttitta
		Art Unit	1618
		Examiner Name	D. Jones
		Kitamura <i>et al.</i> , "Cloning and characterization of cDNA encoding a precursor for human adrenomedullin," <i>Biochem. Biophys. Res. Comm.</i> 194:720-725 (1993)	
		Kitamura <i>et al.</i> , "Adrenomedullin (11-26): a novel endogenous hypertensive peptide isolated from bovine adrenal medulla," <i>Peptides</i> 22:1713-1718 (2001)	
		Lewis <i>et al.</i> , "Degradation of human adrenomedullin (1-52) by plasma membrane enzymes and identification of metabolites," <i>Peptides</i> 18(5):733-739 (1997)	
		Watanabe <i>et al.</i> , "Vasopressor activity of N-terminal fragments of adrenomedullin in anesthetized rat," <i>Biochem. Biophys. Res. Comm.</i> 219:59-63 (1996)	

EXAMINER SIGNATURE: 	DATE CONSIDERED: 2/12/07
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66904-02
Application Number	10/529,118
Filing Date	March 24, 2005
First Named Inventor	Cuttitta
Art Unit	1618
Examiner Name	D. Jones

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,830,703	November 3, 1998	Kitamura <i>et al.</i>
		5,837,823	November 17, 1998	Kitamura <i>et al.</i>
		2002/0055615	May 9, 2002	Cuttitta <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		PCT	WO 2004/043383	May 27, 2004	Cuttitta <i>et al.</i>

OTHER DOCUMENTS



Examiner's Initials*	Cite No. (optional)	
		Belloni <i>et al.</i> , "Proadrenomedullin N-Terminal 20 Peptide (PAMP), Acting Through PAMP(12-20)-Sensitive Receptors, Inhibits Ca ²⁺ -Dependent, Agonist-Stimulated Secretion of Human Adrenal Glands," <i>Hypertension</i> 33:1185-1189 (1999)
		Calvo <i>et al.</i> , "Adrenomedullin and proadrenomedullin N-terminal 20 peptide in the normal prostate and in prostate carcinoma," <i>Microsc. Res. Tech.</i> 57(2):98-104 (April 2002) <i>Abstract Only</i>
		Champion <i>et al.</i> , "Proadrenomedullin NH2-terminal 20 peptide has direct vasodilator activity in the cat," <i>Am J. Physiol.</i> 272(4 Pt 2):R1047-54 (April 1997) <i>Abstract Only</i>


EXAMINER
SIGNATURE:


DATE
CONSIDERED:


2/12/07

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66904-02
		Application Number	10/529,118
		Filing Date	March 24, 2005
		First Named Inventor	Cuttitta
		Art Unit	1618
		Examiner Name	D Jones
		Champion <i>et al.</i> , "Tone-dependent vasodilator responses to proadrenomedullin NH2-terminal 20 peptide in the hindquarters vascular bed of the rat," <i>Peptides</i> 18(4):513-519 (1997) <i>Abstract Only</i>	
		Eto <i>et al.</i> , "Adrenomedullin and proadrenomedullin N-terminal 20 peptide: vasodilatory peptides with multiple cardiovascular and endocrine actions," <i>Trends in Endo and Metab.</i> 12(3):91-93 (April 1, 2001) <i>Abstract Only</i>	
		Fry <i>et al.</i> , "Proadrenomedullin NH2-terminal peptide (PAMP) (12-20) has vasodepressor activity in the rat and cat," <i>Life Science</i> 60(10):PL161-167 (1997) <i>Abstract Only</i>	
		Ishimitsu <i>et al.</i> , "Genomic structure of human adrenomedullin gene," <i>Biochem Biophys Res Commun</i> 203(1):631-639 (August 30, 1994) <i>Abstract Only</i>	
		Kangawa <i>et al.</i> , "Adrenomedullin: a new hypotensive peptide," <i>J. Hypertens Suppl.</i> 14(5):S105-110 (December 1996) <i>Abstract Only</i>	
		Kapas <i>et al.</i> , "Regulation of PAMP and adrenomedullin receptor expression in the rat adrenal zona glomerulosa" <i>Endoc Res.</i> 24(3-4):717-20 (Aug-Nov 1998) <i>Abstract Only</i>	
		Kitamura <i>et al.</i> , "Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP)," <i>FEBS Letters</i> 351(1):35-7 (August 29, 1994) <i>Abstract Only</i>	
		Kuwasako <i>et al.</i> , "Increased plasma proadrenomedullin N-terminal 20 peptide in patients with essential hypertension," <i>Ann Clin Biochem.</i> 36(pt5):622-628 (September 1999) <i>Abstract Only</i>	
		Lisy <i>et al.</i> , "Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin," <i>Am. J. Physiol.</i> 275:F410-F414 (1998)	
		Makino <i>et al.</i> , "Attenuated hypotensive response to proadrenomedullin N-terminal 20 peptide in pregnant rats: modulation by steroid hormones," <i>Peptides</i> 20(12):1521-1525 (1999) <i>Abstract Only</i>	
		Martínez <i>et al.</i> , "Proadrenomedullin NH ₂ -Terminal 20 Peptide is a Potent Angiogenic Factor, and its Inhibition Results in Reduction of Tumor Growth," <i>Cancer Res</i> 64:6489-6496 (September 15, 2004)	
		Martínez <i>et al.</i> , "The Effects of Adrenomedullin Overexpression in Breast Tumor Cells," <i>J. Nat. Cancer Inst.</i> 94(16):12 pages (August 21, 2002)	
			Matsui <i>et al.</i> , "Biosynthesis and Secretion of Adrenomedullin and Proadrenomedullin N-Terminal 20 Peptide in a Rat Model of Endotoxin Shock," <i>Hypertens</i> 24:543-549 (2001)
		Matsui <i>et al.</i> , "Lack of hypotensive effect of chronically infused proadrenomedullin N-terminal 20 peptide in rats," <i>Horm Metab Res</i> 30(9):555-6 (1998) <i>Abstract Only</i>	

EXAMINER SIGNATURE: 	DATE CONSIDERED: 2/2/07
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	


INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-66904-02
		Application Number	10/529,118
		Filing Date	March 24, 2005
		First Named Inventor	Cuttitta
		Art Unit	1618
		Examiner Name	D Jones
		Moody <i>et al.</i> , "Adrenomedullin binds with high affinity, elevates cyclic AMP, and stimulates c-fos mRNA in C6 glioma cells," <i>Peptides</i> 18(8):1111-1115 (1997) <i>Abstract Only</i>	
		Nakamura <i>et al.</i> , "Comparison of vasodilator potency of adrenomedullin and proadrenomedullin N-terminal 20 peptide in human," <i>Life Sci.</i> 65(20):2151-2156 (1999) <i>Abstract Only</i>	
		Nossaman <i>et al.</i> , "Effects of Phentolamine on Responses to PAMP in the Hindquarters Vascular Bed of the Rat," <i>J. Cardiovasc. Pharmacol Ther.</i> 2(3):153-157 (July 1997) <i>Abstract Only</i>	
		Robert <i>et al.</i> , "Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart," <i>Lab Invest.</i> 76(5):729-738 (May 1997) <i>Abstract Only</i>	
		Saita <i>et al.</i> , "Cardiovascular and sympathetic effects of proadrenomedullin NH ₂ -terminal 20 peptide in conscious rats," <i>Regul Pept</i> 77(1-3):147-153 (October 16, 1998) <i>Abstract Only</i>	
		Samson <i>et al.</i> , "Central mechanisms for the hypertensive effects of preproadrenomedullin-derived peptides in conscious rats," <i>Am J. Physiol</i> 274:R1505-R1509 (1998)	
		Samson, "Proadrenomedullin-derived peptides," <i>Front Neuroendocrinol.</i> 19(2):100-27 (April 1998) <i>Abstract Only</i>	
		Shimosawa <i>et al.</i> , "A Newly Identified Peptide, Proadrenomedullin N-Terminal 20 Peptide, Induces Hypotensive Action via Pertussis Toxin-Sensitive Mechanisms," <i>Hypertension</i> 30:1009-1014 (1997)	
		Shimosawa <i>et al.</i> , "Adrenomedullin, an Endogenous Peptide, Counteracts Cardiovascular Damage," <i>Circulation</i> 105:106-111 (2002)	
		Shimosawa and Fujito, "Hypotensive Effect of a Newly Identified Peptide, Proadrenomedullin N-Terminal 20 Peptide," <i>Hypertension</i> 28:325-329 (1996)	
		Uemura <i>et al.</i> , "Aldosterone augments adrenomedullin production without stimulating pro-adrenomedullin N-terminal 20 peptide secretion in vascular smooth muscle cells," <i>J. Hypertens.</i> 20(6):1209-1214 (June 2002) <i>Abstract Only</i>	
		Wilkinson <i>et al.</i> , "Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH ₂ -terminal 20 peptide (PAMP)," <i>J. Clin Pharm</i> 52:159-164 (2001)	
	Zhao <i>et al.</i> , "PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium," <i>Oncogene</i> 16(3):409-415 (January 22, 1998) <i>Abstract Only</i>		

EXAMINER SIGNATURE: 	DATE CONSIDERED: 2/12/07
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-66904-02
	Application Number	10/529,118
	Filing Date	March 24, 2005
	First Named Inventor	Cuttitta
	Art Unit	1618
	Examiner Name	D. Jones

U.S. PATENT DOCUMENTS


Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.


Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,831,004	November 3, 1998	Campbell <i>et al.</i>
		6,117,869	September 12, 2000	Picard <i>et al.</i>
		6,133,304	October 17, 2000	Peterson, Jr., <i>et al.</i>
		6,265,432	July 24, 2001	Purchase, Jr. <i>et al.</i>
		6,307,101	October 23, 2001	Campbell <i>et al.</i>
		6,339,160	January 15, 2002	Politi <i>et al.</i>
		6,350,885	February 26, 2002	O'Brien <i>et al.</i>


FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Corcoran <i>et al.</i> , "MMP-2: Expression, Activation and Inhibition," <i>Enzyme Protein</i> 49:7-19 (1996)
		Giannelli and Antonaci, "Gelatinases and their inhibitors in tumor metastasis: form biological research to medical applications," <i>Histol Histopathol</i> 17:339-345 (2002)
		Kleiner and Stetler-Stevenson, "Matrix metalloproteinases and metastasis," <i>Cancer Chemother Pharmacol</i> 43(Suppl):S42-S51 (1999)
		Kugler <i>et al.</i> , "Matrix Metalloproteinases and their Inhibitors," <i>Anticancer Research</i> 19:1589-1592 (1999)

EXAMINER SIGNATURE: 	DATE CONSIDERED: 2/12/07
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-66904-02
Application Number	10/529,118
Filing Date	March 24, 2005
First Named Inventor	Cuttitta
Art Unit	1618
Examiner Name	D. Jones

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Goffin <i>et al.</i> , "Human Endometrial Epithelial Cells Modulate the Activation of Gelatinase A by Stromal Cells," <i>Gynecol Obstet Invest</i> 53:105-111 (2002)

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.